Patents by Inventor John R. Mackey

John R. Mackey has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • EMERGENCY MEDICATION STORAGE DEVICE FOR CARDIAC CHEST PAIN
    Publication number: 20200121561
    Abstract: A packaging system for emergency access to cardiac medications, where the patient has convenient and safe access to aspirin and nitroglycerin for immediate use at the onset of cardiac chest pain or suspected cardiac chest pain.
    Type: Application
    Filed: April 9, 2019
    Publication date: April 23, 2020
    Inventors: John R. MACKEY, James STEWART
  • Predictive markers for taxane responsiveness and methods of use thereof
    Patent number: 8980564
    Abstract: Taxanes are widely used in the treatment of breast cancer, although there are currently no validated predictive markers for taxane responsiveness. While the mechanism by which taxanes induce mitotic arrest is well documented, the signaling pathway that links mitotic arrest to cell death, is ill-defined. As described herein, the BH3-only protein Bad and Bik are prognostic indicators for overall survival after adjuvant taxane chemotherapy and a predictive marker for taxane responsiveness.
    Type: Grant
    Filed: November 19, 2010
    Date of Patent: March 17, 2015
    Assignees: The Governors of the University of Alberta, Alberta Health Services
    Inventors: Ing Swie Goping, John R. Mackey, D. Alan Underhill
  • PREDICTIVE MARKERS FOR TAXANE RESPONSIVENESS AND METHODS OF USE THEREOF
    Publication number: 20130178515
    Abstract: Taxanes are widely used in the treatment of breast cancer, although there are currently no validated predictive markers for taxane responsiveness. While the mechanism by which taxanes induce mitotic arrest is well documented, the signaling pathway that links mitotic arrest to cell death, is ill-defined. As described herein, the BH3-only protein Bad and Bik are prognostic indicators for overall survival after adjuvant taxane chemotherapy and a predictive marker for taxane responsiveness.
    Type: Application
    Filed: November 19, 2010
    Publication date: July 11, 2013
    Applicants: ALBERTA HEALTH SERVICES, THE GOVERNORS OF THE UNIVERSITY OF ALBERTA
    Inventors: Ing Swie Goping, John R. Mackey, D. Alan Underhill